

**Online Supplement: Author Relationships With Industry and Other Entities (Comprehensive)—
ACC/AHA/AACVPR/AAFP/ANA Concepts for Clinician–Patient Shared Accountability in Performance
Measures**

Name	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Eric. D. Peterson, Chair	Executive Director, Duke Clinical Research Institute	<ul style="list-style-type: none"> • Boehringer Ingelheim • Genentech • Janssen Pharmaceuticals • Johnson & Johnson • Merck 	None	None	<ul style="list-style-type: none"> • Eli Lilly† • Johnson & Johnson† • Janssen Pharmaceuticals† 	<ul style="list-style-type: none"> • DCRI‡ 	None
Mary Barton	National Committee for Quality Assurance, Vice President	None	None	None	None	<ul style="list-style-type: none"> • Kaiser† • National Committee for Quality Assurance† 	None
Craig Beam	Medical Development Specialists—Senior Vice President	None	None	None	None	None	None
L. Hayley Burgess	HCA Clinical Services Group—Director of Medication Safety and System Innovations	None	None	None	None	None	None
Donald E. Casey, Jr.	Atlantic Health—Chief Medical Officer	None	None	None	None	None	None
Joseph P. Drozda, Jr.	Mercy Health—Director, Outcomes Research	None	None	None	<ul style="list-style-type: none"> • FDA/Harvard University (PI)† 	<ul style="list-style-type: none"> • Boston Scientific Rhythm Management† • AMA-PCPI Executive Committee* 	None
Gregg C. Fonarow	Ahmanson-UCLA Cardiomyopathy Center—Director, Division of Cardiology	<ul style="list-style-type: none"> • Amgen • Bayer • Boston Scientific • Johnson & Johnson • Medicines Company • Medtronic • Novartis† • Takeda 	None	None	<ul style="list-style-type: none"> • Gambro • Medtronic • NHLBI† • NIH/NIAID† • Novartis† • PRT* 	<ul style="list-style-type: none"> • ACC* • AHA* • IMPROVE HF Steering Committee* 	None
David Goff, Jr.	Wake Forest University—Professor of Medicine	None	None	None	None	<ul style="list-style-type: none"> • Denver Metro AHA* • Dean, Colorado School of Public Health† 	None
Kathleen L. Grady	Bluhm Cardiovascular Institute—Administrative	None	None	None	<ul style="list-style-type: none"> • AHA† • NHLBI 	<ul style="list-style-type: none"> • AHA* 	None

	Director, Center for Heart Failure						
P. Michael Ho	Stanford University School of Medicine—Professor of Medicine	•Wellpoint Inc..	None	None	None	None	None
Dana King	Medical University of South Carolina—Professor and Vice Chair, Department of Family Medicine	•Pfizer/Boehringer Ingelheim	None	None	None	None	None
Marjorie L. King	Columbia University (Helen Hayes Hospital)—Director, Cardiac Rehabilitation	None	None	None	None	None	None
Frederick A. Masoudi	University of Colorado at Denver—Associate Professor of Medicine, Division of Cardiology	None	None	None	•AHRQ† •NHLBI† •Oklahoma Foundation for Medical Quality†	•ACC† •AHA •Massachusetts Medical Society	• Plaintiff, 2012, Acute Coronary Syndrome, Expert Opinion
David R. Nielsen	The American Academy of Otolaryngology—Chief Executive Officer and Executive Vice President	None	None	None	None	•AAO† •CMSS* •AMA-PCPI*	None
Stephen Stanko	Mended Hearts—Chair, Catheterization Patient Outreach	None	None	None	None	None	None

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. A person is deemed to have a *significant* interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, or ownership of \$10,000 or more of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. A relationship is considered to be *modest* if it is less than significant under the preceding definition. Relationships that exist with no financial benefit are also included for the purposes of transparency. Relationships in this table are modest unless otherwise noted.

*No financial relationship.

†Significant (greater than \$10,000) relationship.

‡DCRI has numerous grants and contracts sponsored by industry. These include the following: Aastrom Biosciences†; Abbott†; Abiomed†; Acorn Cardiovascular†; Adolor Corp.†; Advanced Cardiovascular Systems†; Advanced Stent Technologies†; Adynnx; Aijnomoto†; Allergan†; Amgen†; Alnylam Pharma†; Alpharma†; Amylin Pharmaceuticals†; Anadyst†; Anesiva†; Angel Medical Systems†; ANGES MG†; Angiomedtrix†; APT Nidus Center†; ASCA Biopharma†; Astellas Pharma†; Asklepios†; AstraZeneca†; Atritech†; Attention Therapeutics†; Aventis†; Baxter†; Bayer†; Berlex†; BG Medicine†; Biogen†; Biorex Therapeutics†; Biomarker Factory†; Biosite†; Boehringer Ingelheim Biogen†; Boston Scientific†; Bristol-Myers Squibb†; BMS Pfizer†; Carbomed†; CardioDx†; CardioKinetix†; Cardiovascular Systems†; Cardiovox†; Celsion Corp.†; Centocor†; Cerexa†; Chase Medical†; Conatus Pharmaceuticals†; Conor Medsystems†; Cortex†; Corgentech†; CSL Behring†; CV Therapeutics†; Daiichi Pharmaceuticals†; Daiichi-Sankyo†; Daiichi-Sankyo Lilly†; Datascope; Dendreon†; Dainippon†; Dr. Reddy's Laboratories; Eclipse Surgical Technologies†; Edwards Lifesciences†; Eisai†; Endicor†; EnteroMedics†; Enzon Pharmaceuticals†; Eli Lilly†; Ethicon†; Ev3†; Evalve†; F2G†; Flow Cardia†; Fox Hollow Pharmaceuticals†; Fujisawa†; Genetech†; General Electric†; General Electric Co.†; General Electric Healthcare†; General Electric Medical Systems†; Genzyme Corp.†; Genome Canada†; Gilead Sciences†; GlaxoSmithKline†; Guidant Corp.†; Heartscape Technologies†; Hoffman-LaRoche†; Hospira†; Idera Pharmaceuticals†; Ikaria†; Imcor Pharmaceuticals†; Immunex†; INFORMD†; Inimex†; Inspire Pharmaceuticals†; Ischemix†; Janssen†; Johnson and Johnson†; Jomed†; Juventus Therapeutics†; KAI Pharmaceuticals†; King Pharmaceuticals†; Kyowa Pharma†; Luitpold†;

Mardil†; MedImmune†; Medscape†; Medtronic Diabetes†; Medtronic†; Medtronic Vascular†; Merck Group†; MicroMed Technology†; Millennium Pharmaceuticals†; Mitsubishi Tanabe†; Momenta†; Nabriva†; Neuron Pharmaceuticals†; NitroMed; NovaCardia Inc†; Novartis AG Group†; Novartis Pharmaceuticals†; Oncura†; Orexigen†; Ortho-McNeil-Janssen†; OSI Eyetech†; OSI Pharmaceuticals†; Pfizer†; Pharmacyclics†; Pharmasset†; Pharmsos†; Phyxius Pharmaceuticals; Pharsight†; Pluristen Therapeutics†; Portola Pharmaceuticals†; Proventys†; Radiant†; Regado Biosciences†; Rengeron Pharmaceuticals†; Roche Molecular Systems†; Roche Group†; Roche Diagnostic†; Salix Pharmaceuticals†; Sanofi-Pasteur, Inc; Sanofi-aventis†; Santaris Pharmaceuticals†; Schering-Plough†; Scios†; Siemens†; Southwest Oncology Group†; Spectranetics†; Summit†; Sunovion Pharmaceuticals†; TAP Pharmaceutical Products†; Tengion†; The Medicines Company†; Theravance†; TherOx†; Tethys Bioscience†; Theregen†; Three Rivers Pharmaceuticals†; The EMMES Corporation†; UCB†; Valentis†; Valleylab†; Vertex†; Viacor†; and Wyeth†.

AAO indicate American Academy of Otolaryngology; AACVPR indicates American Association of Cardiovascular and Pulmonary Rehabilitation; AAFP, American Academy of Family Physicians; ACC, American College of Cardiology; ACTION-GWTG; ACTION Get with the Guidelines; AHA, American Heart Association, AHRQ, Agency for Healthcare Research and Quality; AMA-PCPI, American Medical Association—Physician Consortium for Performance Improvement; ANA, American Nurses Association; ASHP, American Society of Health-System Pharmacists; CMSS, Council of Medical Specialty Societies; DCRI, Duke Clinical Research Institute; HCA, Hospital Corporation of America; IMPROVE HF, Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting; NHLBI, National Heart, Lung and Blood Institute; NIAID, National Institute of Allergy and Infectious Diseases; NIH, National Institutes of Health; and PRT, Pharmaceutical Roundtable; UCLA, University of California, Los Angeles.